Molecular responses of vascular smooth muscle cells to paclitaxel-eluting bioresorbable stent materials

Journal of Biomedical Materials Research - Part A

Volumn 69, Issue 3, 2004, Pages 513-524

  Nguyen, Kytai Truong ^a   Shaikh, Nishat ^a   Wawro, Debra ^b   Zhang, Sheng ^a   Schwade, Nathan D ^b   Eberhart, Robert C ^a,c   Tang, Liping ^a,c  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cDNA microarray; Cell proliferation; Paclitaxel; Poly(L lactic acid); Restenosis; Vascular smooth muscle cells

Indexed keywords

ADHESION; BIOMATERIALS; CONTROLLED DRUG DELIVERY; DNA; ENZYME KINETICS; GENES; MUSCLE;

BIORESORBABLE STENT MATERIALS; RESTENOISIS;

CELLS;

MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN TYROSINE KINASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BIODEGRADABLE IMPLANT; BIOSORPTION; CELL ADHESION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MICROTUBULE; POLYMERIZATION; RESTENOSIS; STENT; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 2442636502     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.30020     Document Type: Article

References (42)

1. Casterella PJ. Restenosis: An overview. Front Radiat Ther Oncol 2001;35:147-171.
2. Hamon M, Bauters C, McFadden EP, Wernert N, Lablanche JM, Dupuis B, Bertrand ME. Restenosis after coronary angioplasty. Eur Heart J 1995;16(Suppl I):33-48.
3. El-Omar MM, Dangas G, Iakovou I, Mehran R. Update on in-stent restenosis. Curr Interv Cardiol Rep 2001;3:296-305.
4. Hoffmann R, Mintz GS. Coronary in-stent restenosis-predictors, treatment, and prevention. Eur Heart J 2000;21:1739-1749.
5. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
6. Baumbach A, Herdeg C, Kluge M, Oberhoff M, Lerch M, Haase KK, Wolter C, Schroder S, Karsch KR. Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter Cardiovasc Interv 1999;47:102-106.
7. Oberhoff M, Herdeg C, Baumbach A, Karsch KR. Stent-based antirestenotic coatings (sirolimus/paclitaxel). Catheter Cardiovasc Interv 2002;55:404-408.
8. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106:1788-1793.
9. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
10. Su S, Nguyen KT, Brouse CF, Greilich PE, Tang L, Eberhart RC. Curcumin reduces the proinflammatory property of poly (L-lactic acid) fiber. J Biomater Sci Polymer Edn 2004. Submitted for publication.
11. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zeheb R. Taxol: mechanisms of action and resistance. Ann NY Acad Sci 1986;466:733-744.
12. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-1259.
13. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000;86:879-884.
14. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645.
15. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich JP, Crow MT, Lakatta EG, Rowinsky EK, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-1876.
16. Chieffo A, Colombo A. Drug-eluting stents. Minerva Cardio-angiol 2002;50:419-429.
17. Park S, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
18. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33-37.
19. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 1999;21:48-50.
20. Heller MJ. DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng 2002;4:129-153.
21. Chicurel ME, Dalma-Weiszhausz DD. Microarrays in pharmacogenomics-advances and future promise. Pharmacogenomics 2002;3:589-601.
22. Bakker D, Van Blitterswijk CA, Daems WT, Grote JJ. Biocompatibility of six elastomers in vitro. J Biomed Mater Res 1988; 22:423-439.
23. Nguyen KT, Su S, Sheng A, Wawro D, Schwade ND, Brouse CF, Greilich PE, Tang L, Eberhart RC. In vitro hemocompatibility studies of drug-loaded poly (L-lactic acid) Fibers. Biomaterials 2004. In press.
24. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Lee TJ. Nitric oxide and prostaglandin E2 participate in lipopolysaccharide/ interferon-gamma-induced heme oxygenase 1 and prevent RAW264.7 macrophages from UV-irradiation-induced cell death. J Cell Biochem 2002;86:331-339.
25. Sindermann JR, Skaletz-Rorowski A, Bartels A, Hohage H, Plenz G, Schmidt A, Breithardt G. Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C. Basic Res Cardiol 2002;97:125-131.
26. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-1014.
27. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247-3252.
28. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-1050.
29. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-3782.
30. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134-136.
31. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-79.
32. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999;285:197-203.
33. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 2001;80:442-449.
34. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997;272:14914-14920.
35. Su Y, Zharikov SI, Block ER. Microtubule-active agents modify nitric oxide production in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1183-L1189.
36. Sauro MD, Camporesi DA, Sudakow RL. The anti-tumor agent, taxol, attenuates contractile activity in rat aortic smooth muscle. Life Sci 1995;56:PL157-PL161.
37. Johnson BD, Byerly L. A cytoskeletal mechanism for Ca2+ channel metabolic dependence and inactivation by intracellular Ca2+. Neuron 1993;10:797-804.
38. Hamm-Alvarez SF, Alayof BE, Himmel HM, Kim PY, Crews AL, Strauss HC, Sheetz MP. Coordinate depression of bradykinin receptor recycling and microtubule-dependent transport by taxol. Proc Natl Acad Sci USA 1994;91:7812-7816.
39. O'Brien JM, Jr., Wewers MD, Moore SA, Allen JN. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J Immunol 1995;154: 4113-4122.
40. Kirikae T, Kirikae F, Oghiso Y, Nakano M. Microtubule-disrupting agents inhibit nitric oxide production in murine peritoneal macrophages stimulated with lipopolysaccharide or paclitaxel (Taxol). Infect Immun 1996;64:3379-3384.
41. Nishio K, Arioka H, Ishida T, Fukumoto H, Kurokawa H, Sata M, Ohata M, Saijo N. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 1995;63: 688-693.
42. Rosette C, Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J Cell Biol 1995;128:1111-1119.